Law360, New York (May 2, 2006, 12:00 AM EDT) -- In a move that could bode well for biotechnology company ViaCell Inc. in a long-running battle between umbilical-cord blood banks, the U.S. Patent and Trademark Office has issued a first office action rejecting all of the claims of two patents held by rival PharmaStem Therapeutics Inc., according to a ViaCell press release.
The patents, which cover the collection, cryopreservation and storage of hematopoietic stem cells from umbilical-cord blood, have been a bone of contention between the companies since 2002.
Nicholas Didier, chief executive officer of PharmaStem,...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.